Helen Heslop
Directeur/Membre du Conseil chez The Leukemia & Lymphoma Society, Inc.
Profil
Helen E.
Heslop is the founder of AlloVir, Inc. (founded in 2013) and Tikva Allocell Pte Ltd.
(founded in 2023).
Currently, Dr. Heslop holds the position of Director at The Leukemia & Lymphoma Society, Inc. since 2023.
Additionally, Dr. Heslop is a Director at the Center For Cell & Gene Therapy and Deputy Director at the Dan L.
Duncan Comprehensive Cancer Center.
Postes actifs de Helen Heslop
| Sociétés | Poste | Début |
|---|---|---|
The Leukemia & Lymphoma Society, Inc.
 The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Directeur/Membre du Conseil | 01/07/2023 |
| Dan L. Duncan Comprehensive Cancer Center | Corporate Officer/Principal | - |
| Center For Cell & Gene Therapy | Directeur/Membre du Conseil | - |
Anciens postes connus de Helen Heslop
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOVIR, INC. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALLOVIR, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Commercial Services |
| Center For Cell & Gene Therapy | |
| Dan L. Duncan Comprehensive Cancer Center |
